相似文献
1
Tamoxifen Resistance Trumped and Oral Selective Estrogen Receptor Degraders Arrive.
Clin Cancer Res. 2018 Aug 1;24(15):3480-3482. doi: 10.1158/1078-0432.CCR-18-0759. Epub 2018 Apr 19.
2
BQ323636.1, a Novel Splice Variant to 2, as a Predictor for Tamoxifen-Resistant Breast Cancer.
Clin Cancer Res. 2018 Aug 1;24(15):3681-3691. doi: 10.1158/1078-0432.CCR-17-2259. Epub 2018 Feb 2.
3
SpliceArray profiling of breast cancer reveals a novel variant of NCOR2/SMRT that is associated with tamoxifen resistance and control of ERα transcriptional activity.
Cancer Res. 2013 Jan 1;73(1):246-55. doi: 10.1158/0008-5472.CAN-12-2241. Epub 2012 Nov 1.
4
CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.
Br J Cancer. 2009 Dec 1;101(11):1824-32. doi: 10.1038/sj.bjc.6605423. Epub 2009 Nov 10.
5
Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.
Bioorg Med Chem Lett. 2015 Nov 15;25(22):5163-7. doi: 10.1016/j.bmcl.2015.09.074. Epub 2015 Oct 3.
6
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
J Med Chem. 2015 Jun 25;58(12):4888-904. doi: 10.1021/acs.jmedchem.5b00054. Epub 2015 May 22.
7
8
Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Breast Cancer Res Treat. 2010 Jul;122(2):395-407. doi: 10.1007/s10549-009-0581-0. Epub 2009 Oct 22.
9
Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring?
J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):255-9. doi: 10.1016/s0960-0760(00)00101-1.
10
The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
Best Pract Res Clin Endocrinol Metab. 2004 Mar;18(1):47-66. doi: 10.1016/j.beem.2003.08.002.
引用本文的文献
1
Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy.
J Mol Model. 2019 Aug 28;25(9):278. doi: 10.1007/s00894-019-4156-7.
2
Poly-ADP-Ribosylation of Estrogen Receptor-Alpha by PARP1 Mediates Antiestrogen Resistance in Human Breast Cancer Cells.
Cancers (Basel). 2019 Jan 4;11(1):43. doi: 10.3390/cancers11010043.
3
The Value of Monitoring the Behavior of Circulating Tumor Cells at the End of Endocrine Therapy in Breast Cancer Patients.
Cancers (Basel). 2018 Oct 29;10(11):407. doi: 10.3390/cancers10110407.
4
Successful Targeted Therapies for Breast Cancer: the Worcester Foundation and Future Opportunities in Women's Health.
Endocrinology. 2018 Aug 1;159(8):2980-2990. doi: 10.1210/en.2018-00263.
本文引用的文献
1
Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance.
Nat Rev Cancer. 2018 Jun;18(6):377-388. doi: 10.1038/s41568-018-0001-z.
2
A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER/HER2 Advanced Breast Cancer.
Clin Cancer Res. 2018 Aug 1;24(15):3510-3518. doi: 10.1158/1078-0432.CCR-17-3102. Epub 2018 Feb 13.
3
BQ323636.1, a Novel Splice Variant to 2, as a Predictor for Tamoxifen-Resistant Breast Cancer.
Clin Cancer Res. 2018 Aug 1;24(15):3681-3691. doi: 10.1158/1078-0432.CCR-17-2259. Epub 2018 Feb 2.
4
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.
Cancer Res. 2016 Jun 1;76(11):3307-18. doi: 10.1158/0008-5472.CAN-15-2357. Epub 2016 Mar 28.
5
A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer.
Eur J Cancer. 2014 Nov;50(16):2866-76. doi: 10.1016/j.ejca.2014.08.011. Epub 2014 Sep 6.
6
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1.
7
Tamoxifen: catalyst for the change to targeted therapy.
Eur J Cancer. 2008 Jan;44(1):30-8. doi: 10.1016/j.ejca.2007.11.002.
8
Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation.
Mol Cell. 2007 Sep 7;27(5):691-700. doi: 10.1016/j.molcel.2007.08.012.
9
Structural basis for an unexpected mode of SERM-mediated ER antagonism.
Mol Cell. 2005 May 13;18(4):413-24. doi: 10.1016/j.molcel.2005.04.014.
10
The estrogen receptor: a model for molecular medicine.
Clin Cancer Res. 2003 Jun;9(6):1980-9.
Zotero 插件